Novo Nordisk News

Subscribe to enjoy similar stories. The Delhi High Court on Tuesday allowed domestic drugmaker Dr Reddy’s Laboratories to manufacture and export its generic version of semaglutide to countries where the patent-holder Novo Nordisk does not have patent protection. Notably, semaglutide is the compound behind the Danish drugmaker’s blockbuster weight-loss drug Ozempic.

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday was a watershed moment. Until now, these weight-loss drugs have been available largely to people with means. The launch of affordable generic versions will be a levelling force in healthcare, with global consequences.That’s because the world’s two most-populous countries aren’t just consumers.

Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes. U.S.-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk

Subscribe to enjoy similar stories. In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

NEW DELHI : Danish drug manufacturer Novo Nordisk plans to scale up its operations in India by expanding its collaborations with its existing partners, said John Dawber, corporate vice-president and managing director for Global Business Services (GBS) at Novo Nordisk. Despite facing a significant shortage of its famous and in-demand diabetes and weight-loss drugs globally, collaborations, Dawber told Mint, will be the extent of Novo’s operations in India as it already has “strategic production sites across the globe for manufacturing". “The Indian set-up is the crown jewel of Novo Nordisk.

KKR is all set to acquire Healthium Medtech ( formerly Sutures India) from its current PE owners Apax Partners for Rs 7000 crore ($840 mn) enterprise value after a hotly contested three way race that also included a consortium of Mankind Pharma — ChrysCapital and Novo Holdings, the controlling shareholders of Danish drug major Novo Nordisk, said people aware. KKR and Apax have signed the binding agreement for the acquisition of Bengaluru based Healthium Medtech and likely to make a formal announcement as early as Monday, the people mentioned above added. Healthium is the largest manufacturer of surgical needles globally by volume. Moneycontrol was the first to report on Saturday that KKR was the highest bidder for Healthium.

The Federal Trade Commission is challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic

Obesity is one of the biggest issues for health care professionals, but for those companies at the forefront of tackling it, the returns could be phenomenal.

(Reuters) — S&P 500 and Nasdaq futures edged higher on Thursday ahead of more economic data and commentary from Jerome Powell after the Federal Reserve chair stuck to the script overnight by saying the central bank still expects to cut rates later this year.

Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such drugs, while illegal versions are also sold online. «We're open to any way to reach more patients as long as it makes sense for the company and we can supply the market,» Ricks said when asked if Lilly was open to authorised generic versions of drugs containing tirzepatide, the active ingredient in popular diabetes and weight-loss drugs.

In late January, Eli Lilly (NYSE:LLY) weight-loss drugs helped the Indianapolis-based drugmaker replace Tesla (NASDAQ:TSLA) from the Magnificent 7.

Drugmakers kicked off 2024 by raising the list prices for Ozempic, Mounjaro and dozens of other widely used medicines. Companies including Novo Nordisk, the maker of Ozempic, and Eli Lilly, which sells Mounjaro, raised list prices on 775 brand-name drugs during the first half of January, according to an analysis for The Wall Street Journal by 46brooklyn Research, a nonprofit drug-pricing analytics group. The drugmakers raised prices of their medicines by a median of 4.5%, though the prices of some drugs rose by around 10% or higher, according to the research group.

By Ankika Biswas, Khushi Singh and Bansari Mayur Kamdar

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Ozempic and Wegovy, announced on Thursday that it had filed lawsuits against two pharmacies after tests found the products to be tainted. This is Novo Nordisk's latest legal action against pharmacies gaining popularity. Novo Nordisk said that the lawsuits have been filed against Florida-based Wells Pharmacy Network and Brooksville Pharmaceuticals.

By Klaus Lauer and Ludwig Burger

By Patrick Wingrove

(Reuters) -Eli Lilly on Thursday cut its annual profit outlook on charges related to recent acquisitions, and beat quarterly sales estimates driven by strong demand for its new blockbuster diabetes drug, Mounjaro.

Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment

Reuters. The drugmaker has accused the four compounding pharmacies, which make customized drug preparations for customers, of violating federal and state consumer protection and competition laws by selling unregulated versions of Mounjaro.